MetaCap

Immunome (IMNM) vs Septerna (SEPN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Septerna (SEPN) has outperformed Immunome (IMNM) over the past year, gaining 51.1% versus a loss of 15.3%. Immunome is the larger company by market cap ($1.85 billion vs $1.84 billion), about 1.0 times the size, while Septerna is growing revenue faster (+4174.5% vs -23.2%). Septerna converts more of its revenue into profit, with a net margin of -106.4% versus -3060.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IMNM-15.33%SEPN+51.06%
+111%+45%-21%
Nov 21, 20251 yearNov 20, 2026
IMNM+29.56%SEPN+80.42%
+146%+31%-85%
Oct 21, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IMNM versus SEPN key metrics
MetricIMNMSEPN
Share price$15.69$38.61
Market cap$1.85B$1.84B
1-day change-5.54%-1.51%
YTD return-26.96%+38.49%
1-year return-15.33%+51.06%
5-year return-7.54%—
EPS (TTM)$-2.63$-1.30
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$6.94M$45.95M
Revenue growth (YoY)-23.23%+4174.51%
Net income (latest FY)$-212.39M$-48.88M
Operating margin-3228.83%-148.63%
Net margin-3059.99%-106.37%
52-week high$30.06$53.34
52-week low$15.55$22.78
Distance from 52-week high-47.80%-27.62%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+123.90%+53.38%
Average volume1.36M383.96K
Shares outstanding118.07M47.55M
Employees267134
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SEPN has outperformed IMNM by 66.4 percentage points over the past year.
  • Septerna is more profitable, keeping -106.4 cents of every revenue dollar as net income versus -3060.0 cents for Immunome.
  • Septerna grew revenue faster in its latest fiscal year (+4174.51% vs -23.23%).

About Immunome

IMNM stock →

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.

Health Care · Biotechnology: Pharmaceutical Preparations · 267 employees

About Septerna

SEPN stock →

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 134 employees

IMNM vs SEPN FAQ

Which is bigger, Immunome or Septerna?

Immunome (IMNM) is larger, with a market capitalization of $1.85B compared with $1.84B for Septerna (SEPN).

Which stock has performed better over the past year, IMNM or SEPN?

SEPN returned +51.06% over the past 12 months, compared with -15.33% for IMNM (price return, excluding dividends). Past performance does not predict future results.

Are Immunome and Septerna in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons